Compare SFST & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | CRMD |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.5M | 590.7M |
| IPO Year | 2012 | 2009 |
| Metric | SFST | CRMD |
|---|---|---|
| Price | $60.27 | $4.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $68.75 | $13.80 |
| AVG Volume (30 Days) | 69.8K | ★ 1.9M |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 94.76 | ★ 780.00 |
| EPS | ★ 3.68 | 0.57 |
| Revenue | $6,282,000.00 | ★ $311,709,000.00 |
| Revenue This Year | $23.97 | $8.05 |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | $16.45 | ★ $8.30 |
| Revenue Growth | 12.99 | ★ 617.03 |
| 52 Week Low | $47.01 | $4.72 |
| 52 Week High | $65.09 | $13.02 |
| Indicator | SFST | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 24.97 |
| Support Level | $58.42 | N/A |
| Resistance Level | $63.05 | $8.79 |
| Average True Range (ATR) | 1.68 | 0.53 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 26.06 | 1.10 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.